- Home
- IMNM vs SGMO Comparison
IMNM vs SGMO Comparison
Compare IMNM & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- SGMO
- Stock Information
- Founded
- IMNM 2006
- SGMO 1995
- Country
- IMNM United States
- SGMO United States
- Employees
- IMNM N/A
- SGMO N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMNM Health Care
- SGMO Health Care
- Exchange
- IMNM Nasdaq
- SGMO Nasdaq
- Market Cap
- IMNM 585.5M
- SGMO 488.2M
- IPO Year
- IMNM 2020
- SGMO 2000
- Fundamental
- Price
- IMNM $9.99
- SGMO $1.09
- Analyst Decision
- IMNM Strong Buy
- SGMO Buy
- Analyst Count
- IMNM 5
- SGMO 5
- Target Price
- IMNM $28.60
- SGMO $5.20
- AVG Volume (30 Days)
- IMNM 881.8K
- SGMO 10.5M
- Earning Date
- IMNM 11-13-2024
- SGMO 03-12-2025
- Dividend Yield
- IMNM N/A
- SGMO N/A
- EPS Growth
- IMNM N/A
- SGMO N/A
- EPS
- IMNM N/A
- SGMO N/A
- Revenue
- IMNM $10,129,000.00
- SGMO $52,291,000.00
- Revenue This Year
- IMNM N/A
- SGMO N/A
- Revenue Next Year
- IMNM N/A
- SGMO $5.97
- P/E Ratio
- IMNM N/A
- SGMO N/A
- Revenue Growth
- IMNM N/A
- SGMO N/A
- 52 Week Low
- IMNM $8.97
- SGMO $0.30
- 52 Week High
- IMNM $30.96
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- IMNM 40.28
- SGMO 35.59
- Support Level
- IMNM $9.24
- SGMO $1.00
- Resistance Level
- IMNM $11.06
- SGMO $1.18
- Average True Range (ATR)
- IMNM 0.74
- SGMO 0.16
- MACD
- IMNM -0.06
- SGMO -0.06
- Stochastic Oscillator
- IMNM 31.78
- SGMO 9.89
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.